Astrid Monfort1,2, Kelly Da Silva3, Nicolas Vodovar1,4, Etienne Gayat1,5,6, Alain Cohen-Solal1,2,4,7, Philippe Manivet1,3,6,8. 1. Inserm UMR-S 942, Paris, France. 2. Department of Cardiology, Lariboisière Hospital, Paris, France. 3. Biossip Analytical Platform, Center for Biological Resources BB-0033-00064, Lariboisière Hospital, Paris, France. 4. DHU FIRE, Paris-Diderot University, Paris, France. 5. Department of Anesthesiology & Intensive Care, Lariboisière Hospital, Paris, France. 6. DHU Neurovasc, Paris-Diderot University, Paris, France. 7. Paris Diderot University, Sorbonne Paris Cité, Paris, France. 8. Department of Biochemistry, Lariboisière Hospital, Paris, France.
Abstract
AIM: We have evaluated here the clinical and analytical performance of the Alere™ Heart Check (AHC) test, a rapid point-of-care immunoassay designed for the measurement of BNP from fresh capillary whole blood. PATIENTS & METHODS: One-hundred-and-sixty-three patients with stable chronic heart failure followed at the cardiac rehabilitation were submitted to simultaneous capillary (AHC) and plasma (Abbott architect system) BNP measurements. RESULTS: Both methods showed a good correlation, although the values diverged when BNP was higher than 2000 pg/ml. Despite a relatively poor precision of AHC, however, both methods showed the same performances to assess patients' dyspnea and equivalent sensitivity, specificity, negative and positive predicting values. CONCLUSION: AHC BNP test is a good POC for the management of heart failure despite a relatively poor precision.
AIM: We have evaluated here the clinical and analytical performance of the Alere™ Heart Check (AHC) test, a rapid point-of-care immunoassay designed for the measurement of BNP from fresh capillary whole blood. PATIENTS & METHODS: One-hundred-and-sixty-three patients with stable chronic heart failure followed at the cardiac rehabilitation were submitted to simultaneous capillary (AHC) and plasma (Abbott architect system) BNP measurements. RESULTS: Both methods showed a good correlation, although the values diverged when BNP was higher than 2000 pg/ml. Despite a relatively poor precision of AHC, however, both methods showed the same performances to assess patients' dyspnea and equivalent sensitivity, specificity, negative and positive predicting values. CONCLUSION:AHCBNP test is a good POC for the management of heart failure despite a relatively poor precision.
Authors: Mattia Arrigo; Nicolas Vodovar; Seraina Von Moos; Elisabeth Masson; Stephan Segerer; Pietro E Cippà; Alexandre Mebazaa Journal: J Clin Lab Anal Date: 2018-05-23 Impact factor: 2.352
Authors: Caroline Morbach; Thomas Buck; Christian Rost; Sebastian Peter; Stephan Günther; Stefan Störk; Christiane Prettin; Raimund Erbel; Georg Ertl; Christiane E Angermann Journal: Clin Res Cardiol Date: 2017-11-15 Impact factor: 5.460
Authors: Kathryn S Taylor; Jan Y Verbakel; Benjamin G Feakins; Christopher P Price; Rafael Perera; Clare Bankhead; Annette Plüddemann Journal: BMJ Date: 2018-05-21